NCT03552848 is a NA clinical trial of MSC in Multiple Organ Dysfunction Syndrome, sponsored by Fujian Medical University.

Who is sponsoring NCT03552848?

NCT03552848 is sponsored by Fujian Medical University.

What drugs are being tested in NCT03552848?

Interventions in NCT03552848: MSC.

What condition does NCT03552848 study?

NCT03552848 studies Multiple Organ Dysfunction Syndrome.

Is NCT03552848 still recruiting?

NCT03552848 is currently status unknown. Last updated 18 June 2019.

Last reviewed 2019-06-18 · How we verify

NCT03552848

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection

Status unknown NA Last updated 18 June 2019

What this trial tests

NA trial testing MSC in Multiple Organ Dysfunction Syndrome in 60 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
1 December 2019

1 December 2019

Quick facts

Lead sponsor	Fujian Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	1 July 2018
Primary completion	1 December 2019
Estimated completion	1 December 2019
Sites	1 location across China

Drugs / interventions tested

MSC — full drug profile →

Conditions studied

Multiple Organ Dysfunction Syndrome — all drugs for Multiple Organ Dysfunction Syndrome →

Sponsor

Fujian Medical University

Who can join

Adults 20 to 80, any sex, with Multiple Organ Dysfunction Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple organ dysfunction syndrome (MODS) after surgical repaire for acute type A aortic dissection(ATAAD) is a life-threatening condition. In this study, patients who undergoing surgical repaire of ATAAD immdediately or presenting sever MODS after surgical repaire of acute type A aortic dissection will be treated with umbilical cord-derived mesenchymal stem cell.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome.
Lopes-Pacheco M, Robba C, Rocco PRM, Pelosi P. · · 2020 · cited 61× · PMID 31485828 · DOI 10.1007/s10565-019-09493-5
Current therapeutic strategies for respiratory diseases using mesenchymal stem cells.
Wang MY, Zhou TY, Zhang ZD, Liu HY, et al · · 2021 · cited 21× · PMID 34766151 · DOI 10.1002/mco2.74
The Safety and Efficiency of Addressing ARDS Using Stem Cell Therapies in Clinical Trials
Rezoagli E, Murphy E, Laffey J, O’Toole D. · · 2019

Verify or expand the search:

Other trials of MSC

Trials testing the same drug.

NCT06823063 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD · Phase 1 · not yet recruiting
NCT06813157 — Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia · NA · recruiting
NCT06788470 — Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulm · Phase 1, PHASE2 · recruiting
NCT05697718 — Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke · Phase 1 · completed
NCT04611256 — Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 · Phase 1 · unknown

Other recruiting trials for Multiple Organ Dysfunction Syndrome

Currently open trials in the same condition.

NCT07532174 — Efferon LPS Hemoadsorption in Cardiac Surgery Patients · NA · recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting

Other Fujian Medical University trials

Trials by the same sponsor.

NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03552848 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
Last refreshed: 18 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03552848.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing